H.C. Wainwright raised the firm’s price target on Evolus to $27 from $16 and keeps a Buy rating on the shares post the Q2 results. Jeuveau keeps gaining traction, while Evolysse adds value to the company’s long-term growth strategy, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EOLS:
- Evolus raises FY23 revenue view to $185M-$195M, consensus $189.0M
- Evolus reports Q2 EPS (32c), consensus (19c)
- EOLS Earnings this Week: How Will it Perform?
- Evolus raises FY23 revenue view to $185M-$195M from $180M-$190M
- Evolus reports Q2 revenue $49.3M, consensus $47.55M
Questions or Comments about the article? Write to editor@tipranks.com